The Harvard/MIT Broad Institute won a court case validating their CRSPR patents, and EDIT (Editas) is one way to be exposed to that. Its hard to develop a good comparison, but the competition licensed technology from the loser and look at the valuation grid:

CRSPR is increasingly looking like a viable medical technology that can be instrumental in curing and treating a plethora of conditions. Editas seems like an asymmetric bet where, if it doesn't work out, in five years it still will be near a billion market cap and if it does work out, the stock could be up 4X or more. After you buy, the key is to be patient and wait a few years.